-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TXf83IKd6Cez8dF7I31FML4EpvfIK+YRxJGbrjOp90Nh1S8Y6MlpJofOUqXydu1j O/PQDecfKtX0OUh9nOKlYg== 0001246360-09-002438.txt : 20090805 0001246360-09-002438.hdr.sgml : 20090805 20090805170450 ACCESSION NUMBER: 0001246360-09-002438 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090803 FILED AS OF DATE: 20090805 DATE AS OF CHANGE: 20090805 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: OESTERLE STEPHEN N CENTRAL INDEX KEY: 0001174532 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-07707 FILM NUMBER: 09988948 MAIL ADDRESS: STREET 1: MEDTRONIC INC STREET 2: 710 MEDTRONIC PKWY, MS LC310 CITY: MINNEAPOLIS STATE: MN ZIP: 55432-5604 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MEDTRONIC INC CENTRAL INDEX KEY: 0000064670 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 410793183 STATE OF INCORPORATION: MN FISCAL YEAR END: 0430 BUSINESS ADDRESS: STREET 1: 710 MEDTRONIC PKWY STREET 2: MS LC300 CITY: MINNEAPOLIS STATE: MN ZIP: 55432 BUSINESS PHONE: 7635144000 MAIL ADDRESS: STREET 1: 710 MEDTRONIC PKWY CITY: MINNEAPOLIS STATE: MN ZIP: 55432 4 1 form.xml PRIMARY DOCUMENT X0303 4 2009-08-03 false 0000064670 MEDTRONIC INC MDT 0001174532 OESTERLE STEPHEN N 710 MEDTRONIC PKWY MS LC310 MINNEAPOLIS MN 55432 false true false false SrVP Medicine & Technology Common Stock 1070.134 I ESOP Common Stock 200 I IRA Common Stock 4218 I Trust Common Stock 2009-08-03 4 A false 6960 0 A 47991.501 D Employee Stock Option (right to buy) 35.92 2009-08-03 4 A false 27840 0 A 2010-08-03 2019-08-03 Common Stock 27840 27840 D These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. This balance increased by 669.902 due to exempt transactions. The restrictions on these units shall lapse 100% on the third anniversary of the grant date if the Company?s cumulative diluted earnings per share growth during the 36 month period ending on the last day of the Company?s fiscal year 2012 equals or exceeds a 5% compound annual growth rate, as determined by the Compensation Committee. James N. Spolar, Attorney-in-fact 2009-08-05 -----END PRIVACY-ENHANCED MESSAGE-----